Latest Breaking News On - Ian karp - Page 2 : comparemela.com

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in

Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single doseA single dose of NTLA-2002 led to 95% mean reduction

United kingdomIan karpAlina liMatt crensonJohn leonardDrug administrationRegulatory agencyEuropean medicines agencyEuropean commissionIntellia therapeutics incCorporate communicationsClinical programEuropean academy of allergyClinical immunology hybrid congressExchange commissionNew england journal

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomMatt crensonIan karpJohn leonardAlina liEuropean medicines agencyEuropean commissionExchange commissionClinical immunology hybrid congressCorporate communicationsRegulatory agencyIntellia therapeutics incDrug administrationEuropean academy of allergyClinical programTherapeutics announces publication

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNIT.

United kingdomCity ofIan karpJohn leonardAlina liMatt crensonCorporate communicationsIntellia therapeutics incExchange commissionRegeneron pharmaceuticals incVivo program updatesCompany at the marketDrug administrationEuropean medicines agencyClinical trial applicationIntellia president

Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November

Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomIan karpAlina liJulian gillmoreMatt crensonNational amyloidosis centreCorporate communicationsDevelopment of serumIntellia therapeutics incDivision of medicinePresent updated dataOngoing phaseHold conference callDiscuss third quarterClinical data updateLatest data

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development CAMBRIDGE, Mass., Oct. 18, 2023 Intellia.

United kingdomUnited statesAlina liMatt crensonIan karpJohn leonardDrug administrationIntellia therapeutics incExchange commissionCorporate communicationsGlobenewswire incInvestigational new drugIntellia presidentChief executive officerNobel prize winningPrivate securities litigation reform act